ClinicalTrials.gg
CompletedNCT03657160Updated Jun 6, 2023Results posted

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

A Phase 3 interventional study of Vedolizumab Placebo and Vedolizumab in Hematopoietic Stem Cells, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 139 sites in 27 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who are undergoing allo-HSCT transplantation. This study will look at the efficacy and safety of vedolizumab in the prophylaxis of intestinal aGvHD in participants undergoing allo-HSCT transplantation.

The study will enroll approximately 558 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need) along with background GvHD prophylaxis regimen:

  • Vedolizumab 300 mg
  • Placebo (dummy inactive intravenous infusion)

This multi-center trial will be conducted Worldwide. The overall time to participate in this study is 12 months.

02

Conditions studied

  • Hematopoietic Stem Cells

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be >= 18 years of age and, in selected countries, adolescents aged 12 years and greater and weighing >=30 kilogram (kg) at time of randomization.
  2. Must undergo deoxyribose nucleic acid (DNA)-based human leukocyte antigen (HLA) matching and be 8 of 8 or 7 of 8 HLA-matched (singe allele or antigen mismatch at HLA-A, -B, and -C, and HLA-DRB1 is allowable) unrelated hematopoietic stem cell transplantation () from either peripheral blood or bone marrow stem cells for a hematologic or myeloproliferative disorder.
  3. For whom a myeloablative conditioning or reduced intensity conditioning (RIC) is planned.
  4. Allo-HSCT eligible (meeting institutional criteria)-participants planned medical care should include aGvHD prophylaxis with a combination of calcineurin inhibitor (CNI) (cyclosporine [CYS] or tacrolimus [TAC]) and methotrexate (MTX) or CNI and mycophenolate mofetil (MMF). With the exception of antithymocyte globulin (ATG) (antithymocyte globulin-Fresenius [ATG-F] or thymoglobulin), all other therapies, approved or , for GvHD prophylaxis are excluded.
  5. (ECOG) performance status of \<= 2 for participants aged >=18 years at randomization or >=60 % using the performance status for adolescent participants aged >=16 years at randomization or the Lansky performance status for adolescent participants aged 12 to \< 16 years at randomization.

Exclusion criteria

Exclusion Criteria:

  1. Had prior allo- .
  2. Planned umbilical cord blood transplant or planned to receive posttransplant cyclophosphamide, in vivo or ex vivo T cell-depleted hematopoietic stem cells (HSCs) with the exception of ATG (ATG-F or thymoglobulin).
  3. Planned allo-HSCT for nonmalignant hematological disorders (example, aplastic anemia, sickle cell anemia, thalassemias, Fanconi anemia or immunodeficiency).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
343 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).

    Drug: Vedolizumab Placebo

  • Experimental
    Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once on Day -1 along with background GvHD prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).

    Drug: Vedolizumab

Interventions

  • DrugVedolizumab Placebo

    Vedolizumab placebo-matching IV infusion.

  • Vedolizumab IV infusion.

    Also known as: MLN0002

06

What researchers measure

Primary outcomes

  1. Intestinal aGvHD-Free Survival After Allo-HSCT by +180 Days

    Intestinal aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death, where an event is defined as death due to any cause or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria. Data was censored for participants who have not had the intestinal aGvHD event or died or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.

    Time frame: From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to +180 days

Secondary outcomes

  1. Intestinal aGvHD-Free and Relapse-Free Survival

    Intestinal aGvHD and Relapse Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death/relapse, where an event is defined as death or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria, or relapse. It will be censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo-HSCT whichever occurs first.

    Time frame: From the date of first dose of study drug to first documented intestinal aGvHD, death or relapse, whichever occurs first up to Day +180

  2. Grade C-D aGvHD-Free Survival

    Grade C-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to GvHD event/death, where an event is defined as Grade C-D aGvHD any organ involvement per International Bone Marrow Transplant Registry Database (IBMTR) Severity Index for aGvHD or death. It will be censored for participants who have not had the event or have had the event after pre-specified timing, eg, last contact or Day +180 after allo-HSCT whichever occurs first.

    Time frame: From the date of first dose of study drug to first documented Grade C-D aGvHD or death, whichever occurs first up to Day +180

  3. Nonrelapse Mortality (NRM)

    Non-relapse mortality is the time from the date of first study drug administration (Day-1) to death without occurrence of a relapse. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.

    Time frame: From the date of first dose of study drug to first documented death without relapse, up to Day +180

  4. Overall Survival (OS)

    Overall Survival by Days +180 is the time from the date of first study drug administration (Day-1) to death from any cause.

    Time frame: From the date of first dose of study drug to first documented death up to Day +180

  5. Grade B-D aGvHD-Free Survival

    Grade B-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to aGvHD event or death, where an event is defined as death or grade B-D any organ involvement per IBMTR Severity Index for aGvHD.

    Time frame: From the date of first dose of study drug to first documented grade B-D aGvHD or death, whichever occurs first up to Day +180

07

Results

Posted Apr 14, 2023

Participant flow

Participants took part in the study at 95 investigative sites in Canada, United States, Argentina, Brazil, Belgium, France, Germany, Italy, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, Austria, Greece, Hungary, Poland, Israel, Romania, Russia, Australia, Japan, Republic of Korea and Singapore from 6 February 2019 to 9 May 2022.

Participant flow — Overall Study
MilestonePlaceboVedolizumab 300 mg
Started169174
Safety analysis set165169
Full analysis set165168
Completed98117
Not completed7157
Withdrew: Adverse event56
Withdrew: Protocol deviation30
Withdrew: Withdrawal by subject1816
Withdrew: Site termination10
Withdrew: Unsatisfactory therapeutic response53
Withdrew: Death3326
Withdrew: Death (covid-19-related)10
Withdrew: Reason not specified55
Withdrew: Other (covid-19-related)01

Outcome measures

PrimaryIntestinal aGvHD-Free Survival After Allo-HSCT by +180 Days

Intestinal aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death, where an event is defined as death due to any cause or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria. Data was censored for participants who have not had the intestinal aGvHD event or died or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.

Time frame:
From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to +180 days
Reported as:
Median · days
Intestinal aGvHD-Free Survival After Allo-HSCT by +180 Days
daysPlaceboVedolizumab 300 mg
Intestinal aGvHD-Free Survival After Allo-HSCT by +180 DaysNA (14 to 182)NA (2 to 182)
Statistical analysis
  • Placebo vs Vedolizumab 300 mg · Log Rank · p = <0.001 · Hazard ratio (hr): 0.45 · 95% CI 0.27 to 0.73
SecondaryIntestinal aGvHD-Free and Relapse-Free Survival

Intestinal aGvHD and Relapse Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death/relapse, where an event is defined as death or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria, or relapse. It will be censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo-HSCT whichever occurs first.

Time frame:
From the date of first dose of study drug to first documented intestinal aGvHD, death or relapse, whichever occurs first up to Day +180
Reported as:
Median · days
Intestinal aGvHD-Free and Relapse-Free Survival
daysPlaceboVedolizumab 300 mg
Intestinal aGvHD-Free and Relapse-Free SurvivalNA (14 to 182)NA (2 to 182)
Statistical analysis
  • Placebo vs Vedolizumab 300 mg · Log Rank · p = 0.0043 · Hazard ratio (hr): 0.56 · 95% CI 0.37 to 0.86
SecondaryGrade C-D aGvHD-Free Survival

Grade C-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to GvHD event/death, where an event is defined as Grade C-D aGvHD any organ involvement per International Bone Marrow Transplant Registry Database (IBMTR) Severity Index for aGvHD or death. It will be censored for participants who have not had the event or have had the event after pre-specified timing, eg, last contact or Day +180 after allo-HSCT whichever occurs first.

Time frame:
From the date of first dose of study drug to first documented Grade C-D aGvHD or death, whichever occurs first up to Day +180
Reported as:
Median · days
Grade C-D aGvHD-Free Survival
daysPlaceboVedolizumab 300 mg
Grade C-D aGvHD-Free SurvivalNA (12 to 182)NA (12 to 182)
Statistical analysis
  • Placebo vs Vedolizumab 300 mg · Log Rank · p = 0.0204 · Hazard ratio (hr): 0.59 · 95% CI 0.39 to 0.91
SecondaryNonrelapse Mortality (NRM)

Non-relapse mortality is the time from the date of first study drug administration (Day-1) to death without occurrence of a relapse. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.

Time frame:
From the date of first dose of study drug to first documented death without relapse, up to Day +180
Reported as:
Median · days
Nonrelapse Mortality (NRM)
daysPlaceboVedolizumab 300 mg
Nonrelapse Mortality (NRM)NA (14 to 182)NA (19 to 182)
Statistical analysis
  • Placebo vs Vedolizumab 300 mg · Log Rank · p = 0.0668 · Hazard ratio (hr): 0.48 · 95% CI 0.22 to 1.04
SecondaryOverall Survival (OS)

Overall Survival by Days +180 is the time from the date of first study drug administration (Day-1) to death from any cause.

Time frame:
From the date of first dose of study drug to first documented death up to Day +180
Reported as:
Median · days
Overall Survival (OS)
daysPlaceboVedolizumab 300 mg
Overall Survival (OS)NA (14 to 182)NA (19 to 182)
Statistical analysis
  • Placebo vs Vedolizumab 300 mg · Log Rank · p = 0.1458 · Hazard ratio (hr): 0.63 · 95% CI 0.34 to 1.17
SecondaryGrade B-D aGvHD-Free Survival

Grade B-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to aGvHD event or death, where an event is defined as death or grade B-D any organ involvement per IBMTR Severity Index for aGvHD.

Time frame:
From the date of first dose of study drug to first documented grade B-D aGvHD or death, whichever occurs first up to Day +180
Reported as:
Median · days
Grade B-D aGvHD-Free Survival
daysPlaceboVedolizumab 300 mg
Grade B-D aGvHD-Free SurvivalNA (12 to 182)NA (12 to 182)
Statistical analysis
  • Placebo vs Vedolizumab 300 mg · Log Rank · p = 0.0105 · Hazard ratio (hr): 0.64 · 95% CI 0.46 to 0.91

Adverse events

Collected over From the first dose of study drug up to end of study (up to 39 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo34/169 (20.1%)114/165 (69.1%)164/165 (99.4%)
Vedolizumab 300 mg26/174 (14.9%)120/169 (71%)169/169 (100%)
Most frequent serious events
Showing 10 of 209
Most frequent serious events
EventPlaceboVedolizumab 300 mg
Acute graft versus host disease in intestineImmune system disorders16/1656/169
PyrexiaGeneral disorders13/16513/169
SepsisInfections and infestations9/1654/169
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/1659/169
Alanine aminotransferase increasedInvestigations4/1659/169
Febrile neutropeniaBlood and lymphatic system disorders8/1657/169
PneumoniaInfections and infestations8/1655/169
Acute kidney injuryRenal and urinary disorders8/1653/169
DiarrhoeaGastrointestinal disorders4/1656/169
Cytomegalovirus infection reactivationInfections and infestations2/1656/169
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPlaceboVedolizumab 300 mg
DiarrhoeaGastrointestinal disorders102/16595/169
StomatitisGastrointestinal disorders90/16590/169
NauseaGastrointestinal disorders83/16585/169
PyrexiaGeneral disorders62/16580/169
AnaemiaBlood and lymphatic system disorders72/16568/169
Acute Graft Versus Host Disease in SkinImmune system disorders65/16567/169
Febrile NeutropeniaBlood and lymphatic system disorders54/16567/169
HypomagnesaemiaMetabolism and nutrition disorders52/16560/169
HeadacheNervous system disorders58/16558/169
VomitingGastrointestinal disorders55/16541/169

Baseline characteristics

Full Analysis Set (FAS) included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo-HSCT.

Age, Continuous
Age, Continuous(years)PlaceboVedolizumab 300 mgTotal
Mean51.9 ± 14.4950.8 ± 14.4151.4 ± 14.44
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVedolizumab 300 mgTotal
Female106103209
Male5965124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboVedolizumab 300 mgTotal
Hispanic or Latino91625
Not Hispanic or Latino133133266
Unknown or Not Reported231942
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboVedolizumab 300 mgTotal
American Indian or Alaska Native000
Asian362965
Native Hawaiian or Other Pacific Islander000
Black or African American235
White114121235
More than one race000
Unknown or Not Reported131528
08

Study locations

139 sites
  • University of Alabama at Birmingham Comprehensive Cancer Center
    Birmingham, Alabama 35294, United States
  • David Geffen School of Medicine at University of California Los Angeles
    Los Angeles, California 90095, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Emory University - Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Augusta University Georgia Cancer Center
    Augusta, Georgia 30912, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • Marlene and Stewart Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Columbia University Medical Center - The Columbia Center for Translational Immunology
    New York, New York 10032, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Massey Cancer Center
    Richmond, Virginia 23298, United States
  • Fundacion Favaloro Hospital Universitario
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1093AAS, Argentina
  • Hospital Italiano de Buenos Aires
    Ciudad Autonoma de Buenos Aires, C1199ABB, Argentina
  • Hospital Privado Centro Medico de Cordoba
    Cordoba, X5014KEH, Argentina
  • Saint Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4006, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Ordensklinikum Linz Elisabethinen
    Linz, Upper Austria 4020, Austria
  • Universitair Ziekenhuis Leuven
    Leuven, Flemish Brabant 3000, Belgium
  • Ziekenhuisnetwerk Stuivenberg
    Antwerpen, 2060, Belgium
  • Hospital Universitario Walter Cantidio - Universidade Federal do Ceara
    Fortaleza, Ceara 60430-380, Brazil
  • Instituto do Cancer e Transplante de Curitiba
    Curitiba, Parana 80510-130, Brazil
  • Hospital de Cancer de Barretos
    Barretos, SAO Paulo 14784-400, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
    Sao Paulo, 01246-000, Brazil
  • Fundacao Antonio Prudente - A.C.Camargo Cancer Center
    Sao Paulo, 01509-010, Brazil
  • Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncolgia
    Sao Paulo, 03102-006, Brazil
  • Hospital Santa Marcelina
    Sao Paulo, 08270-070, Brazil
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Saskatchewan Cancer Agency
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Hopital Pontchaillou
    Rennes Cedex 9, Bretagne 35033, France
  • Hopital Saint Louis
    Paris Cedex 10, Ile-de-france 75475, France
  • Hopital Saint-Antoine
    Paris, Ile-de-france 75012, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, Ile-de-france 75013, France
  • Hopital Necker-Enfants Malades
    Paris, Ile-de-france 75473 cedex 15, France
  • Centre Hospitalier Universitaire de Limoges
    Limoges Cedex, Limousin, Lorraine 87042, France
  • Centre Hospitalier Universitaire Nantes - Hotel Dieu
    Nantes Cedex 1, PAYS DE LA Loire 44093, France
  • Centre Hospitalier Universitaire Amiens-Picardie
    Amiens, Picardie 80054 CEDEX 1, France
  • Universitatsmedizin Mannheim
    Mannheim, Baden-wuerttemberg 68167, Germany
  • Diakonie-Klinikum Stuttgart
    Stuttgart, Baden-wuerttemberg 70176, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz
    Mainz, Rheinland-pfalz 55131, Germany
  • Universitatsklinikum Halle
    Halle, Sachsen-anhalt 06120, Germany
  • Universitatsklinikum Carl Gustav Carus Dresden
    Dresden, Sachsen 01307, Germany
  • Universitaetsklinikum Schleswig-Holstein - Campus Kiel
    Kiel, Schleswig-holstein 24105, Germany
  • University General Hospital of Athens Attikon
    Athens, Attica 12462, Greece
  • University Regional General Hospital of Patras
    Patras, Peloponnese 26504, Greece
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdu-bihar 4032, Hungary
  • Soroka University Medical Center
    Beer Sheva, Beersheba 84101, Israel
  • Rambam Health Care Campus - Rambam Medical Center
    Haifa, 3109601, Israel
  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
  • The Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Azienda Grande Ospedale Metropolitano Bianchi Melacrino Morelli
    Reggio Calabria, Calabria 89122, Italy
  • Azienda Ospedaliera Cardinale G. Panico
    Tricase, Lecce 73039, Italy
  • Ospedale Mazzoni
    Ascoli Piceno, Marche 63100, Italy
  • Ospedale dell'Angelo
    Mestre, Venezia 30174, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
    Ancona, 60126, Italy
  • Azienda Ospedaliera Policlinico di Bari
    Bari, 70124, Italy
  • Policlinico Universitario di Catania
    Catania, 95124, Italy
  • Istituto Clinico Humanitas Humanitas Cancer Center
    Milano, 20089', Italy
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Presidio Ospedaliero di Pescara
    Pescara, 65125, Italy
  • Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital
    Nagoya, Aichi 453-8511, Japan
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital
    Hiroshima-shi, Hiroshima 730-8619, Japan
  • Hokkaido University Hospital
    Sapporo-shi, Hokkaido 060-8648, Japan
  • Okayama University Hospital
    Okayama-city, Okayama 700-8558, Japan
  • Shizuoka Cancer Center
    Nagaizumi, Shizuoka 411-8777, Japan
  • Jichi Medical University Hospital
    Shimotsuke-city, Tochigi 329-0498, Japan
  • Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
    Bunkyo-Ku, Tokyo 113-8677, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Gyeonggi-do 03080, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, Gyeongsangbuk-do 41944, Korea, Republic of
  • Keimyung University Dongsan Hospital
    Daegu, Gyeongsangbuk-do 42601, Korea, Republic of
  • Pusan National University Hospital
    Busan, Gyeongsangnam-do 49241, Korea, Republic of
  • Daegu Catholic University Medical Center
    Daegu, 42472, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea - Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of

Showing the first 100 of 139 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Feb 2022, 36 months.

Results were first posted in Apr 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2018
First posted
Sep 4, 2018
StartActual
Feb 6, 2019
Primary completionActual
Feb 7, 2022
CompletionActual
May 9, 2022
Results first posted
Apr 14, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03657160
Responsible party
Sponsor
First posted
Sep 4, 2018
Start date
Feb 6, 2019
Primary completion
Feb 7, 2022
Completion
May 9, 2022
Results posted
Apr 14, 2023
Last update
Jun 6, 2023

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion